Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma

BACKGROUND: Lenvatinib and atezolizumab plus bevacizumab(A + B) have been used for unresectable hepatocellular carcinoma (HCC) as first‐line therapy. Real‐world studies comparison of efficacy and safety in these two regimens are limited, we therefore conduct this study to investigate these issues. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Chung‐Wei, Teng, Wei, Lin, Po‐Ting, Jeng, Wen‐Juei, Chen, Kuei‐An, Hsieh, Yi‐Chung, Chen, Wei‐Ting, Ho, Ming‐Mo, Hsieh, Chia‐Hsun, Wang, Ching‐Ting, Chai, Pei‐Mei, Lin, Chen‐Chun, Lin, Chun‐Yen, Lin, Shi‐Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067067/
https://www.ncbi.nlm.nih.gov/pubmed/36468578
http://dx.doi.org/10.1002/cam4.5506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067067/
https://www.ncbi.nlm.nih.gov/pubmed/36468578
http://dx.doi.org/10.1002/cam4.5506

Ejemplares similares